Bright Minds Biosciences (DRUG) Expected to Announce Earnings on Thursday

Bright Minds Biosciences (NASDAQ:DRUG) is anticipated to post its Q1 2026 results before the market opens on Thursday, February 12th. Analysts expect Bright Minds Biosciences to post earnings of ($0.98) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, February 10, 2026 at 12:30 PM ET.

Bright Minds Biosciences Stock Performance

Shares of NASDAQ:DRUG opened at $76.00 on Thursday. Bright Minds Biosciences has a 52-week low of $23.17 and a 52-week high of $123.75. The company has a market capitalization of $739.48 million, a P/E ratio of -62.30 and a beta of -6.18. The company has a 50-day simple moving average of $82.69 and a 200 day simple moving average of $61.14.

Analyst Ratings Changes

Several analysts have issued reports on the company. Robert W. Baird set a $142.00 price objective on Bright Minds Biosciences in a research note on Wednesday, January 7th. Chardan Capital restated a “buy” rating and issued a $80.00 price target on shares of Bright Minds Biosciences in a research note on Friday, January 2nd. Wall Street Zen downgraded Bright Minds Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. BTIG Research lifted their price objective on shares of Bright Minds Biosciences from $72.00 to $147.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Zacks Research lowered shares of Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 2nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $121.00.

Institutional Trading of Bright Minds Biosciences

A number of institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in shares of Bright Minds Biosciences during the third quarter worth approximately $58,000. JPMorgan Chase & Co. raised its holdings in Bright Minds Biosciences by 624.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after acquiring an additional 1,873 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Bright Minds Biosciences during the 2nd quarter valued at $66,000. New York State Common Retirement Fund acquired a new stake in shares of Bright Minds Biosciences during the 2nd quarter worth $107,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Bright Minds Biosciences by 949.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,796 shares of the company’s stock worth $291,000 after purchasing an additional 4,339 shares in the last quarter. Institutional investors own 40.52% of the company’s stock.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.